LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG

Their core work

The Ludwig Boltzmann Gesellschaft (LBG) is Austria's applied research society, operating specialized Ludwig Boltzmann Institutes that bridge fundamental science with clinical and societal applications. Their H2020 portfolio reveals strong capabilities in biomedical research — from bone regeneration and immunology to rare disease diagnostics — combined with a surprising depth in digital humanities and cultural heritage technologies. They contribute experimental and translational research expertise to large European consortia, often bringing clinical or patient-oriented perspectives to technically driven projects. Their work spans tissue engineering, biomaterials for implants, digital curation using machine learning, and newborn genetic screening platforms.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), LBG focused on fundamental biomedical mechanisms — ER stress pathways, bone regeneration, AIDS vaccine development, and corneal therapies. From 2019 onward, their portfolio shifted decisively toward applied health technologies, particularly rare disease diagnostics (newborn screening, digital health records) and advanced manufacturing for medical implants (3D bioprinting, ceramic additive manufacturing). A parallel track in digital humanities emerged mid-period, with their largest-funded coordinated project (VHH) applying machine learning to cultural heritage curation.

LBG is converging toward digitally-enabled health applications — combining their biomedical foundations with data platforms, machine learning diagnostics, and advanced biomanufacturing, making them a strong partner for digital health and medtech consortia.

How they like to work

LBG operates almost exclusively as a consortium partner (13 of 15 projects), contributing specialized research expertise rather than leading project management. With 320 unique partners across 40 countries, they function as a well-connected hub — comfortable joining large, diverse consortia and adapting to different project cultures. Their two coordinated projects (RejuvenateBone, VHH) were smaller in consortium size, suggesting they take the lead when the topic aligns closely with their institute-level strengths.

LBG has built an exceptionally broad network of 320 unique consortium partners spanning 40 countries, placing them among the most internationally connected Austrian research organizations in H2020. Their partnerships extend well beyond Central Europe, with collaborations reaching across all major EU member states and associated countries.

What sets them apart

LBG's distinguishing feature is their unusual combination of deep biomedical research with digital technology capabilities — few research centres can contribute meaningfully to both an AIDS vaccine project and a machine-learning cultural heritage platform. Their institute-based structure means they bring focused, sustained expertise rather than individual researcher contributions, offering consortium partners reliable institutional capacity. For health and medtech consortia, they offer a rare Austrian partner with both clinical research depth and growing digital health competence.

Highlights from their portfolio

• VHH
  Their largest-funded project (EUR 995K) and a coordinator role, applying machine learning and automated analysis to Holocaust visual history — an unusual intersection of digital technology and cultural heritage.
• SCREEN4CARE
  Represents their strategic direction: combining newborn genetic screening with digital platforms and ML-based diagnostics to accelerate rare disease identification.
• iDysChart
  Their second-largest funding (EUR 757K), mapping key molecules of human immune dysregulation — reflects their core strength in immunology and translational research.